4Joseph JM, Gross N, Lassau N, et al. In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neurohlastoma xenografts[J]. Int J Cancer,2005,113(6) : 881-890.
5Sirotnak FM, She Y, Khokhar NZ, et al. Microarray analysis of prostate cancer progression to reduced androgen dependence: studies in unique models contrasts early and late molecular events[J]. Mol Carcinog,2004,41(3):150-163.
6Domingguez-Escring JL, Kelly D. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer [J]. Clin Cancer Res,2004 ,10(14) :4874-4884.
7Borowsky ME, Elliott KS, Pezzullo JC. A retrospective review of 15 years of radical radiotherapy with or without concurrent cisplatin and/or 5-fluorouracil for the treatment of locally advanced cervical cancer[J]. Bull Cancer, 2005,92 (2) : 19-24.
8Cadron I, Jakobsen A,Vergote I. Report of an early stopped randomized trial comparing cisplatin vs. cisplatin/ifosfamide/ 5-fluorouracil in recurrent cervical cancer[J]. Gynecol Obstet Invest, 2005,59(3) :126-129.
9Sit AS, Kelley JL, GallionHH, et al. Chemotherapy for recurrent or persistent cervical cancer[J]. Cancer Invest,2004, 22(3):477-478.
10Bradford MM.A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-dye Binding[J].Anal Biochem, 1976,7(72): 248-254.
